Pages that link to "Q33991344"
Jump to navigation
Jump to search
The following pages link to Nephrotoxicity of intravenous colistin: a prospective evaluation (Q33991344):
Displaying 50 items.
- Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients (Q24673399) (← links)
- Renal and neurological side effects of colistin in critically ill patients (Q27499294) (← links)
- Role of Oxidative Stress in Drug-Induced Kidney Injury (Q28074502) (← links)
- Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections (Q33416170) (← links)
- Colistin in the 21st century (Q33847509) (← links)
- Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients (Q34015375) (← links)
- Colistin dosing and nephrotoxicity in a large community teaching hospital (Q34150958) (← links)
- Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study (Q34686057) (← links)
- Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study (Q34955582) (← links)
- Melatonin attenuates colistin-induced nephrotoxicity in rats. (Q35191353) (← links)
- Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing (Q35541277) (← links)
- The use of intravenous colistin among children in the United States: results from a multicenter, case series (Q35592264) (← links)
- Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics (Q35662008) (← links)
- High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. (Q35977417) (← links)
- Global challenge of multidrug-resistant Acinetobacter baumannii (Q36095081) (← links)
- Treatment options for multidrug-resistant bacteria. (Q36607401) (← links)
- Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients (Q36667079) (← links)
- The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections (Q36750086) (← links)
- Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol (Q36818945) (← links)
- Resurgence of colistin use. (Q37009606) (← links)
- Treatment options for multidrug-resistant Acinetobacter species (Q37058001) (← links)
- Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells. (Q37124019) (← links)
- Current control and treatment of multidrug-resistant Acinetobacter baumannii infections (Q37330689) (← links)
- Update on the treatment of Pseudomonas aeruginosa pneumonia (Q37516904) (← links)
- Current treatment of pseudomonal infections in the elderly. (Q37529775) (← links)
- Multidrug-resistant Gram-negative infections: the use of colistin. (Q37785545) (← links)
- Global spread of drug-resistant Acinetobacter baumannii: molecular epidemiology and management of antimicrobial resistance. (Q37869910) (← links)
- Multidrug-resistant bacterial infection in solid organ transplant recipients (Q38006192) (← links)
- Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis (Q38186636) (← links)
- Adverse reactions associated with systemic polymyxin therapy. (Q38255373) (← links)
- A review on colistin nephrotoxicity (Q38501685) (← links)
- Strategies for the safe use of colistin (Q38548658) (← links)
- The safety of polymyxin antibiotics (Q38586123) (← links)
- Use of Colistin in a Neonatal Intensive Care Unit: A Cohort Study of 65 Patients (Q38992007) (← links)
- Recent advances and perspectives in the design and development of polymyxins. (Q39190865) (← links)
- Place of Colistin-Rifampicin Association in the Treatment of Multidrug-Resistant Acinetobacter Baumannii Meningitis: A Case Study (Q39615925) (← links)
- Nephrotoxicity of High and Conventional Dosing Regimens of Colistin: A Randomized Clinical Trial (Q41990979) (← links)
- Colistin nephrotoxicity increases with age. (Q42204009) (← links)
- Colistin therapy for multidrug-resistant Gram-negative infection: clinical outcome and risk factors (Q42247699) (← links)
- Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration (Q42762545) (← links)
- Effectiveness and safety of colistin: prospective comparative cohort study (Q43124623) (← links)
- Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. (Q43249112) (← links)
- Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. (Q45974680) (← links)
- Development of HPLC with fluorescent detection using NBD-F for the quantification of colistin sulfate in rat plasma and its pharmacokinetic applications. (Q48128185) (← links)
- Efficacy and nephrotoxicity associated with various colistin dosing schemas for the treatment of multidrug resistant (MDR) infections (Q49926443) (← links)
- TGF-β-mediated NADPH oxidase 4-dependent oxidative stress promotes colistin-induced acute kidney injury (Q50062993) (← links)
- Nephrotoxicity associated with intravenous colistin in critically ill patients (Q50990199) (← links)
- Quinolone-resistant clinical strains of Pseudomonas aeruginosa isolated from University Hospital in Tunisia. (Q53716911) (← links)
- Incidence and risk factors of nephrotoxicity in patients on colistimethate sodium. (Q54255583) (← links)
- Hypoalbuminemia as a predictor of acute kidney injury during colistin treatment (Q58790968) (← links)